Estimating Pulmonary Function, Interleukin-6 (IL-6), And Superoxide Dismutase-3 (EC-SOD3) Levels in Patients with Chronic Bronchial Asthma on Curcumin Adjuvant Therapy

Abstract

This study was designed to evaluate the effectiveness of curcumin supplement as antioxidant and anti-inflammatory in patients with chronic bronchial asthma. Forty patients diagnosed with chronic bronchial asthma were enrolled in this study and allocated into group (1) patients assigned to receive conventional therapy of asthma, and group (2) patient assigned to receive conventional therapy of asthma combined with 750 mg curcumin supplement twice daily for two months. Pulmonary function test, asthma control test, serum interleukin-6 and serum extracellular super oxide dismutase 3 were measured before and after two months in both study groups. After two months, the mean values of pulmonary function test (spirometry) and asthma control score showed significant increase compared to pre-treatment values in group 2 patients (P<0.01). Moreover, there was marked decrease in the level of interleukin-6 in group 2 patients after two months (p< 0.05) compared to the increased in group 1 patients. The mean level of super oxide dismutase 3 didn’t show any increase in both study groups after treatment. Curcumin supplement produced improvement in pulmonary function of patients with chronic bronchial asthma along with the reduction in inflammatory status. No change in endogenous oxidative status after curcumin supplementation.

Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far?

“…71 In another study, the administration of curcumin (1.5 mg/day) and piperine (5 mg/day) for 2 months resulted in the efficient alleviation of IL-6 and improvement in forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and asthma control test scores in bronchial asthma patients compared to those who received regular asthma drugs. 72 Moreover, this formulation (1−1.5 g/day curcumin with 5 mg/day piperine) reduced the symptoms including weakness, dry cough, sore throat, sputum cough, ague muscular pain, headache, dyspnea, deterioration, and hospitalized duration in COVID-19 patients without side effects. 73,74 Besides, the treatment with this formulation significantly improved mouth opening flexibility, cheek flexibility, and tongue protrusion capacity and suppressed burning sensation in oral submucous fibrosis (OSF) patients compared to placebo (starch and lactose capsules).…”

Role of Turmeric and Curcumin in Prevention and Treatment of Chronic Diseases: Lessons Learned from Clinical Trials

“…Moreover, 1000 mg/day of curcumin along with standard therapy for 30 days produced a remarkable reduction in ESR, eosinophils, and adverse events and improved weight and forced expiratory volume in 60 patients with bronchial asthma . Another study showed that curcumin 1500 mg/day along with piperine 5 mg/day for 30 days remarkably decreased expression of IL-6 and increased forced expiratory volume in one second (FEV1), forced vital capacity, and asthma control test score in bronchial asthma ( n = 40) . In addition, the consumption of curcumin 375 mg thrice daily for 12 weeks was shown to improve chronic anterior uveitis .…”

“…422 Another study showed that curcumin 1500 mg/day along with piperine 5 mg/day for 30 days remarkably decreased expression of IL-6 and increased forced expiratory volume in one second (FEV1), forced vital capacity, and asthma control test score in bronchial asthma (n = 40). 423 In addition, the consumption of curcumin 375 mg thrice daily for 12 weeks was shown to improve chronic anterior uveitis. 424 In another study, a turmeric formulation prepared as an eye drop was effective against eye infections and inflammation in addition to being safe and well tolerated in patients with ophthalmic diseases.…”

Curcuma longa and curcumin affect respiratory and allergic disorders, experimental and clinical evidence: A comprehensive and updated review

“…The ratio of FEV1/FVC was also increased by 12.7% in patients on curcumin supplementation. 39 In a preliminary clinical study, 15 adult patients with stable and persistent asthma with evidence of allergic sensitization were randomly received curcumin (1000 mg, twice daily) or placebo for 6 months. The treatment did not affect post-bronchodilator FEV1 (primary endpoint) and rescue use of bronchodilators.…”